Skip to main content
  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
Logo image Logo image
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline (Opens in a new tab/window)
      • PBM Guidelines (Opens in a new tab/window)
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines (Opens in a new tab/window)
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Search

  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline
      • PBM Guidelines
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

NBA’s AI Transparency Statement

  • Home
  • NBA’s AI Transparency Statement

The Digital Transformation Agency's Policy for the responsible use of AI in government(Opens in a new tab/window) sets out the Australian Government approach to embrace the opportunities of AI and provide for safe and responsible use of AI. 

The National Blood Authority (NBA) is committed to identifying ethical, responsible and meaningful use when considering the adoption of AI capabilities. We will be transparent as we explore, adopt and integrate AI technology to benefit staff and external stakeholders.

Currently, the NBA does not use AI in any services we provide. We are in the process of exploring the potential appropriate use of AI in the NBA context, the risks that will need to be managed, and the benefits it may bring. 

If the NBA implements any AI capability, this statement will be updated to outline our use including:

  • the intentions behind why the NBA is using AI or is considering its adoption
  • classification1 of AI use according to usage patterns and domains
  • classification1 of use where the public may directly interact with, or be significantly impacted by, AI without a human intermediary or intervention
  • measures to monitor the effectiveness of deployed AI systems, such as governance or processes
  • compliance with applicable legislation and regulation
  • efforts to identify and protect the public against negative impacts
  • compliance with each requirement under the Policy for the responsible use of AI in government(Opens in a new tab/window).

Accountable official

The Chief Information Officer is designated as the accountable official.

AI transparency statement

This AI transparency statement was first published to our website in January 2025. This statement will be reviewed annually, or when we make any significant change to our approach to AI as outlined above.

Contact Us

If you have any enquiries about this statement, we can be reached via the details on contact us page of this website

 

[1] As per the Classification system for AI use | digital.gov.au(Opens in a new tab/window)

Last updated: 07 Jan 2025

Back to top

The National Blood Authority acknowledges the Traditional Owners and Custodians of Country throughout Australia, and their continuing connection to land, water and community. We pay our respects to the people, the cultures and the elders past, present and emerging.

National Blood Authority

  • About the NBA
  • Work with us
  • Contact Us
  • Data and reporting
  • Freedom of information
  • Public interest disclosure
  • Resources
  • Accessibility
  • Privacy
  • Copyright
  • Disclaimer
  • BloodPortal Terms and Conditions of Use

Information

  • Blood Products
  • Managing blood supply
  • Supply systems
  • Clinical guidance
  • Patient information
  • Data and research
  • Website feedback